Table 2.
Effect of 10 years' treatment with metformin or chlorpropamide, glibenclamide, or insulin in overweight patients with newly diagnosed type 2 diabetes
| Any diabetes related end point (%) | Deaths related to diabetes (%) | All cause mortality (%) | Myocardial infarction (%) | Stroke (%) | Microvascular disease (%) | Median haemoglobin A1c (%) | |
|---|---|---|---|---|---|---|---|
| Dietary advice plus metformin | 28.7† | 8.2* | 14.6† | 11.4* | 3.5‡ | 7.0 | 7.4 |
| Dietary advice plus chlorpropamide, glibenclamide, or insulin | 36.8 | 10.8 | 20.0 | 14.6 | 6.3 | 7.8 | All similar to metformin |
| Dietary advice only | 38.9 | 13.4 | 21.7 | 17.8 | 5.6 | 9.2 | 8.0 |
| Relative risk reduction (metformin v dietary advice) | 26.2 | 38.8 | 32.7 | 36.0 | 44.4§ | NS | Significantly lower for all drugs compared with dietary advice |
| Absolute risk reduction (metformin v dietary advice) | 10.2 | 5.2 | 7.1 | 6.4 | 2.8§ | NS | |
| No needed to treat for 10 years to prevent one event (metformin v dietary advice) | 10 | 19 | 14 | 16 | 36§ | NS |
*
Significant versus dietary advice.
†
Significant versus both other groups.
‡
Significant versus chlorpropamide, glibenclamide, or insulin group.
§
These results are for the differences between the metformin and the chlorpropamide, glibenclamide, or insulin group.